Truist lowered the firm's price target on Genesco to $32 from $38 and keeps a Hold rating on the shares after its "solid" Q4 results. The company's Journeys group continues to generate strong momentum with premium product assortments fueling higher average sales prices and robust full-priced selling, though the firm remains cautious on the choppy macro, the analyst tells investors in a research note.
